ELCC 2025 – AstraZeneca gets a survival boost from Laura
At last year’s ASCO, AstraZeneca’s Tagrisso showed a trend towards an overall survival benefit in the phase 3 Laura trial, in stage III EGFR-mutated NSCLC, despite a high level of crossover – and now the numbers have improved. The latest results, at 31% maturity, found a 33% reduction in the risk of death with Tagrisso versus placebo – however, the 95% confidence interval’s upper bound still exceeded 1.00, according to data released by Astra ahead of full presentation at the upcoming European Lung Cancer Congress in Paris. Still, this is a move in the right direction for Laura, which takes aim at an earlier setting than Tagrisso’s already established use in first-line metastatic EGFRm NSCLC, where it’s being challenged by Johnson & Johnson’s Rybrevant plus Lazcluze. Tagrisso got the FDA nod in stage III disease in September, based on an overwhelming progression-free survival benefit in Laura. The trial will continue to assess overall survival, and Astra will hope that the numbers improve further.
Evolving OS data from Laura in stage III EGFRm NSCLC
| Venue | ELCC 2025 | ASCO 2024 |
|---|---|---|
| Data maturity | 31% | 20% |
| Crossover from placebo to Tagrisso | 78% | 81% |
| Median OS (months) | 58.8 with Tagrisso vs 54.1 with placebo | 54.0 with Tagrisso vs NR with placebo |
| Stats | HR=0.67; CI=0.40-1.14 | HR=0.81; CI=0.42-1.56 |
Source: ELCC 2025 & ASCO 2024.
932
